Cinotti G A, Bossini A, Cagli V, Corea L, Di Veroli C, Morabito S, Pierucci A, Porcellati C, Savino K, Timio M
Policlinico Umberto I, Roma.
Minerva Med. 1989 Jan;80(1):53-63.
One-hundred patients suffering from slight-moderate hypertension (53 m, 47 f, aged between 18 and 78, average 49.08) have been studied in order to assess the effectiveness and tolerance of lisinopril ("Zestril", ICI-Pharma), a new ACE inhibitor in a single daily administration at doses of between 10 and 80 mg in relation to pressure values. Monotherapy with Lisinopril proved effective in 84 patients (88.4%), in 74 of whom (7.9%) pressure values were returned to normal. 11 patients (11.6%) did not respond to treatment. In most cases, the result was obtained with a dose of 20 mg in a single administration (32.6%). The incidence of side-effects was limited and in no case required the withdrawal of the drug.
为评估新型血管紧张素转换酶(ACE)抑制剂赖诺普利(“捷赐瑞”,ICI制药公司生产)每日单次服用10至80毫克剂量相对于血压值的有效性和耐受性,对100例轻中度高血压患者(53例男性,47例女性,年龄在18至78岁之间,平均49.08岁)进行了研究。单用赖诺普利治疗在84例患者(88.4%)中有效,其中74例(7.9%)血压值恢复正常。11例患者(11.6%)对治疗无反应。在大多数情况下,单次服用20毫克剂量即可取得疗效(32.6%)。副作用发生率有限,在任何情况下均无需停药。